Ratings by JPMorgan (Priyanka Grover)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Neurogene | NGNE | New Coverage | Overweight (N/A) |
25.45 (26.40) |
3.73% | Details | |
| 10/1/2026 | Enliven Therapeutics | ELVN | New Coverage | Overweight (N/A) |
46.51 (40.98) |
-11.89% | Details | |
| 10/1/2026 | Kura Oncology | KURA | New Coverage | Overweight (N/A) |
10.81 (10.60) |
-1.94% | Details | |
| 8/18/2026 | Mereo BipPharma Group | MREO | Downgrade | Underweight (Neutral) |
0.31 (0.35) |
12.9% | Details | |
| 8/18/2026 | Nuvation Bio Inc | NUVB | New Coverage | Overweight (N/A) |
6.22 (5.00) |
-19.61% | Details | |
| 8/14/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/27/2026 | Rhythm Pharmaceuticals | RYTM | New Coverage | Overweight (N/A) |
102.66 (90.78) |
-11.57% | Details | |
| 7/8/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
8.41 (3.31) |
-60.64% | Details | |
| 7/8/2026 | Relay Therapeutics | RLAY | New Coverage | Overweight (N/A) |
18.90 (17.88) |
-5.4% | Details | |
| 4/30/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | Mereo BipPharma Group | MREO | Downgrade | Neutral (Overweight) |
0.36 (0.31) |
-13.89% | Details | |
| 12/17/2025 | Recursion Pharmaceuticals | RXRX | Upgrade | Overweight (Neutral) |
4.20 (4.36) |
3.81% | Details | |
| 8/25/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2025 | Mereo BipPharma Group | MREO | New Coverage | Overweight (N/A) |
2.35 (0.36) |
-84.68% | Details |
